Elderly people losing their vision from age-related might one day have a treatment option that requires fewer injections into the eye than the standard drug now used.
In testing, an experimental drug being developed by , when injected every eight weeks, proved as effective as the standard treatment, Lucentis from , which was injected every four weeks. The findings are from two clinical trials that Regeneron is expected to announce on Monday.
In a separate development, Advanced Cell Technology is expected to announce Monday that it has won regulatory approval to test a therapy derived from human embryonic in people with Stargardt’s macular dystrophy, another retina disease.
It is only the second trial of a therapy derived from human embryonic stem cells to be cleared by the . The first involves a treatment for developed by .
Age-related macular degeneration is the leading cause of in the elderly. Lucentis can restore a person’s ability to drive and read, in some cases.
No comments:
Post a Comment